Ovid Therapeutics Inc. Financial Ratios
OVID|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-38.7%
Profit Margin
-4670.1%
Net Income / Revenue
Asset Turnover
0.00
Revenue / Total Assets
Equity Multiplier
2.21
Total Assets / Equity
Composite: -38.7% (reported: -38.7%)
Profitability
Liquidity
Current Ratio
8.97
Quick Ratio
8.97
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.00
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2025 · SEC 10-K · Updated Jun 28, 2026
Earnings Quality
Accrual Ratio
+24.3%
+31.4pp YoY
Earnings include a notable portion of accrual components.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.